pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›valemetostat
drug
save

valemetostat

Phase 2updated 3mo ago
by Daiichi Sankyo Co Ltd
Phase 2
community read0 votes

indications

indications
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying valemetostat

  • phase1A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancerrecruitingn=24
  • phase1Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Canceractive not recruitingn=17
  • phase1A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)recruitingn=60
  • phase2Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.recruitingn=900
  • phase2A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphomarecruitingn=60
  • phase2A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)active not recruitingn=438
  • phase2Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphomaactive not recruitingn=141
  • phase1A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumorsrecruitingn=210
more trials →

News(0)

no news has mentioned this drug yet

generic
valemetostat [INN]
indication
Non-Small Cell Lung Cancer
phase
phase_2
Data sources
ClinicalTrials.gov
last refreshed 37m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?